File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Generation, secretion and degradation of cancer immunotherapy target PD-L1

TitleGeneration, secretion and degradation of cancer immunotherapy target PD-L1
Authors
KeywordsCancer immunotherapy
Degradation
PD-L1
Regulation mechanisms
Structure
Issue Date1-Aug-2022
PublisherSpringer
Citation
Cellular and Molecular Life Sciences, 2022, v. 79, n. 8 How to Cite?
Abstract

Cancer immunotherapy is a rapidly developing and effective method for the treatment of a variety of malignancies in recent years. As a significant immune checkpoint, programmed cell death 1 ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) play the most significant role in cancer immune escape and cancer immunotherapy. Though PD-L1 have become an important target for drug development and there have been various approved drugs and clinic trials targeting it, and various clinical response rate and adverse reactions prevent many patients from benefiting from it. In recent years, combination trials have become the main direction of PD-1/PD-L1 antibodies development. Here, we summarized PD-L1 biofunctions and key roles in various cancers along with the development of PD-L1 inhibitors. The regulators that are involved in controlling PD-L1 expression including post-translational modification, mRNA level regulation as well as degradation and exosome secretory pathway of PD-L1 were focused. This systematic summary may provide comprehensive understanding of different regulations on PD-L1 as well as a broad prospect for the search of the important regulator of PD-L1. The regulatory factors of PD-L1 can be potential targets for immunotherapy and increase strategies of immunotherapy in combination.


Persistent Identifierhttp://hdl.handle.net/10722/340044
ISSN
2023 Impact Factor: 6.2
2023 SCImago Journal Rankings: 2.274
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorShen, DD-
dc.contributor.authorBi, YP-
dc.contributor.authorPang, JR-
dc.contributor.authorZhao, LJ-
dc.contributor.authorZhao, LF-
dc.contributor.authorGao, Y-
dc.contributor.authorWang, B-
dc.contributor.authorLiu, HM-
dc.contributor.authorLiu, Y-
dc.contributor.authorWang, N-
dc.contributor.authorZheng, YC-
dc.contributor.authorLiu, HM-
dc.date.accessioned2024-03-11T10:41:15Z-
dc.date.available2024-03-11T10:41:15Z-
dc.date.issued2022-08-01-
dc.identifier.citationCellular and Molecular Life Sciences, 2022, v. 79, n. 8-
dc.identifier.issn1420-682X-
dc.identifier.urihttp://hdl.handle.net/10722/340044-
dc.description.abstract<p>Cancer immunotherapy is a rapidly developing and effective method for the treatment of a variety of malignancies in recent years. As a significant immune checkpoint, programmed cell death 1 ligand 1 (PD-L1) and its receptor programmed cell death protein 1 (PD-1) play the most significant role in cancer immune escape and cancer immunotherapy. Though PD-L1 have become an important target for drug development and there have been various approved drugs and clinic trials targeting it, and various clinical response rate and adverse reactions prevent many patients from benefiting from it. In recent years, combination trials have become the main direction of PD-1/PD-L1 antibodies development. Here, we summarized PD-L1 biofunctions and key roles in various cancers along with the development of PD-L1 inhibitors. The regulators that are involved in controlling PD-L1 expression including post-translational modification, mRNA level regulation as well as degradation and exosome secretory pathway of PD-L1 were focused. This systematic summary may provide comprehensive understanding of different regulations on PD-L1 as well as a broad prospect for the search of the important regulator of PD-L1. The regulatory factors of PD-L1 can be potential targets for immunotherapy and increase strategies of immunotherapy in combination.</p>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofCellular and Molecular Life Sciences-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCancer immunotherapy-
dc.subjectDegradation-
dc.subjectPD-L1-
dc.subjectRegulation mechanisms-
dc.subjectStructure-
dc.titleGeneration, secretion and degradation of cancer immunotherapy target PD-L1-
dc.typeArticle-
dc.identifier.doi10.1007/s00018-022-04431-x-
dc.identifier.pmid35819633-
dc.identifier.scopuseid_2-s2.0-85133944772-
dc.identifier.volume79-
dc.identifier.issue8-
dc.identifier.eissn1420-9071-
dc.identifier.isiWOS:000843321700001-
dc.publisher.placeBASEL-
dc.identifier.issnl1420-682X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats